FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291001331> ?p ?o ?g. }

• W4291001331 endingPage "10" @default.
• W4291001331 startingPage "1" @default.
• W4291001331 abstract "Background and Aim. Anlotinib, a novel tyrosine kinase inhibitor, has demonstrated encouraging antitumor activity in bone and soft tissue sarcomas in several prospective clinical trials. This retrospective study is aimed at analyzing the clinical efficacy and safety of treating refractory bone and soft tissue sarcoma with anlotinib in different treatment patterns. Methods. The medical data of 47 patients with refractory bone and soft tissue sarcoma, who received anlotinib from January 2019 to December 2020, were retrospectively collected. The overall response rate (ORR) and disease control rate (DCR) were evaluated according to the solid tumor response evaluation version 1.1 standard. The progression-free survival (PFS), overall survival (OS), and adverse reactions were recorded. Results. A total of 44 patients, including 13 with osteosarcoma and 31 with soft tissue sarcoma, were enrolled in this study. Among patients with osteosarcoma, no patients achieved complete response (CR) or partial response (PR), while seven patients (54%) had stable disease (SD). Besides, the median PFS (m-PFS) was 4.4 months, and the median OS (m-OS) was 15.7 months. Among patients with soft tissue sarcoma, the ORR and DCR were 19% and 71%, respectively. The median m-PFS was 5.4 months, and m-OS was 17.9 months. Anlotinib plus chemotherapy had a higher ORR compared with anlotinib monotherapy (6% vs. 38%, <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>P</mi> <mo>=</mo> <mn>0.047</mn> </math> ). The most common grade 3/4 adverse reactions were pneumothorax (5%) and pleural effusion (5%), and no treatment-related deaths occurred. Conclusions. Anlotinib alone showed encouraging efficacy and favorable tolerability in refractory bone and soft tissue sarcoma. Anlotinib plus chemotherapy did not show a significant clinical benefit compared with anlotinib alone. Anlotinib showed better tumor control when used as first-line drug treatment in refractory bone and soft tissue sarcoma." @default.
• W4291001331 created "2022-08-13" @default.
• W4291001331 creator A5065925117 @default.
• W4291001331 creator A5081847054 @default.
• W4291001331 creator A5083613613 @default.
• W4291001331 date "2022-08-11" @default.
• W4291001331 modified "2023-09-30" @default.
• W4291001331 title "Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns" @default.
• W4291001331 cites W1998360186 @default.
• W4291001331 cites W2107230638 @default.
• W4291001331 cites W2135140316 @default.
• W4291001331 cites W2144530818 @default.
• W4291001331 cites W2167348613 @default.
• W4291001331 cites W2294806546 @default.
• W4291001331 cites W2338929304 @default.
• W4291001331 cites W2528424364 @default.
• W4291001331 cites W2592814855 @default.
• W4291001331 cites W2750123753 @default.
• W4291001331 cites W2755514319 @default.
• W4291001331 cites W2808043936 @default.
• W4291001331 cites W2890746729 @default.
• W4291001331 cites W2901259053 @default.
• W4291001331 cites W2904481169 @default.
• W4291001331 cites W2914703963 @default.
• W4291001331 cites W2948990828 @default.
• W4291001331 cites W2949282276 @default.
• W4291001331 cites W2952461028 @default.
• W4291001331 cites W2980787834 @default.
• W4291001331 cites W3006180429 @default.
• W4291001331 cites W3007595469 @default.
• W4291001331 cites W3028506047 @default.
• W4291001331 cites W3044391932 @default.
• W4291001331 cites W3045712044 @default.
• W4291001331 cites W3062076402 @default.
• W4291001331 cites W3113773454 @default.
• W4291001331 cites W3128376340 @default.
• W4291001331 cites W3135398751 @default.
• W4291001331 cites W3202987832 @default.
• W4291001331 cites W3210251887 @default.
• W4291001331 cites W3214567114 @default.
• W4291001331 cites W4200270124 @default.
• W4291001331 cites W4200334310 @default.
• W4291001331 cites W4200478090 @default.
• W4291001331 cites W4205432101 @default.
• W4291001331 cites W4206229929 @default.
• W4291001331 doi "https://doi.org/10.1155/2022/3287961" @default.
• W4291001331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35991143" @default.
• W4291001331 hasPublicationYear "2022" @default.
• W4291001331 type Work @default.
• W4291001331 citedByCount "3" @default.
• W4291001331 countsByYear W42910013312022 @default.
• W4291001331 countsByYear W42910013312023 @default.
• W4291001331 crossrefType "journal-article" @default.
• W4291001331 hasAuthorship W4291001331A5065925117 @default.
• W4291001331 hasAuthorship W4291001331A5081847054 @default.
• W4291001331 hasAuthorship W4291001331A5083613613 @default.
• W4291001331 hasBestOaLocation W42910013311 @default.
• W4291001331 hasConcept C121332964 @default.
• W4291001331 hasConcept C126322002 @default.
• W4291001331 hasConcept C136948725 @default.
• W4291001331 hasConcept C141071460 @default.
• W4291001331 hasConcept C142424586 @default.
• W4291001331 hasConcept C142724271 @default.
• W4291001331 hasConcept C143998085 @default.
• W4291001331 hasConcept C197934379 @default.
• W4291001331 hasConcept C2777760704 @default.
• W4291001331 hasConcept C2778256501 @default.
• W4291001331 hasConcept C2778629024 @default.
• W4291001331 hasConcept C2909636867 @default.
• W4291001331 hasConcept C535046627 @default.
• W4291001331 hasConcept C71924100 @default.
• W4291001331 hasConcept C87355193 @default.
• W4291001331 hasConceptScore W4291001331C121332964 @default.
• W4291001331 hasConceptScore W4291001331C126322002 @default.
• W4291001331 hasConceptScore W4291001331C136948725 @default.
• W4291001331 hasConceptScore W4291001331C141071460 @default.
• W4291001331 hasConceptScore W4291001331C142424586 @default.
• W4291001331 hasConceptScore W4291001331C142724271 @default.
• W4291001331 hasConceptScore W4291001331C143998085 @default.
• W4291001331 hasConceptScore W4291001331C197934379 @default.
• W4291001331 hasConceptScore W4291001331C2777760704 @default.
• W4291001331 hasConceptScore W4291001331C2778256501 @default.
• W4291001331 hasConceptScore W4291001331C2778629024 @default.
• W4291001331 hasConceptScore W4291001331C2909636867 @default.
• W4291001331 hasConceptScore W4291001331C535046627 @default.
• W4291001331 hasConceptScore W4291001331C71924100 @default.
• W4291001331 hasConceptScore W4291001331C87355193 @default.
• W4291001331 hasLocation W42910013311 @default.
• W4291001331 hasLocation W42910013312 @default.
• W4291001331 hasLocation W42910013313 @default.
• W4291001331 hasOpenAccess W4291001331 @default.
• W4291001331 hasPrimaryLocation W42910013311 @default.
• W4291001331 hasRelatedWork W2020287923 @default.
• W4291001331 hasRelatedWork W2030251285 @default.
• W4291001331 hasRelatedWork W2110516926 @default.
• W4291001331 hasRelatedWork W2147963345 @default.
• W4291001331 hasRelatedWork W2285856986 @default.
• W4291001331 hasRelatedWork W2383467646 @default.

• next